Baricitinib + lonafarnib

1 paper3 findings

PubChem 44205240 PubChem 148195 ChEBI 95341 ChEBI 47097

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Institutes of Health and 1 more

Animals1

Outcomes

Inflammation

downin mice1

1 study

Baricitinib + lonafarnib decreases inflammation in mice.
“Bar + FTI combination therapy most effectively lowered progerin levels, preserved colonic architecture and epithelial regeneration markers, while also reducing inflammation, cellular senescence, and early fibrotic changes.”
AnimalsLmnaG609G/G609G micecolon
Baricitinib Augments Lonafarnib Therapy to Preserve Colonic Homeostasis and Microbial Balance in a Mouse Model of Progeria
Aging cell20 Oct 2025